Skip to main content

Advertisement

SpringerLink
Log in

Prevalence of secondary hematologic disorders in the antiphospholipid syndrome: Impact on coagulation risk

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Hematologic abnormalities may occur in antiphospholipid antibody syndrome. The most common of these abnormalities is thrombocytopenia. The mechanism by which low platelet counts occur is not known but studies continue to elucidate the potential role of autoantibodies and cell surface markers. The risk for thrombosis in patients with thrombocytopenia does not appear to be related to the presence of thrombocytopenia itself. Innovative treatment with anti-CD20 antibodies may be of benefit in reversing thrombocytopenia and treatment with splenectomy does not appear to increase the risk for subsequent thrombosis. Hemolytic anemia is associated with antiphospholipid antibodies as well, but the risk for thrombosis in patients with hemolytic anemia is not clearly elevated. Diagnostic features of disseminated intravascular coagulation may co-occur with the antiphospholipid syndrome and may be associated with a catastrophic clinical presentation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Atsumi T, Furukawa S, Amengual O, et al.: Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus 2005, 14:499–504. A concise review of the association between APS, thrombocytopenia, and thrombosis. This report summarizes possible pathogenic mechanisms for these phenomena and management considerations.

    Article  PubMed  CAS  Google Scholar 

  2. Reiger M, Mannucci PM, Kremer Hovinga JA, et al.:ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005, 106:1262–1267.

    Article  Google Scholar 

  3. Amoura Z, Costedoat-Challumeau N, Veyradier A, et al.:Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. Arthritis Rheum 2004, 50:3260–3264. Case report of two patients with well documented primary APS who met criteria for TTP, including the absence of ADAMTS-13 activity and the presence of acquired autoantibodies to ADAMTS-13. This report adds APS to the list of primary autoimmune disorders that can co-occur with TTP.

    Article  PubMed  Google Scholar 

  4. Coppo P, Clauvel J, Bengoufa D, et al.: Autoimmune cytopenias with autoantibodies to nuclear envelope polypeptides. Am J Hematol 2004, 77:241–249.

    Article  PubMed  CAS  Google Scholar 

  5. Bidot CJ, Jy W, Horstman LL, et al.: Antiphospholipid antibodies inimmune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission. Br J Haematol 2004, 128:366–372.

    Article  Google Scholar 

  6. Nakamura M, Tanaka Y, Satoh T, et al.: Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism. Rheumatology 2005, doi 10.1093/rheumatology/kei118. This study examined the prevalence, clinical associations and pathogenic roles of autoantibodies to CD40L in patients with SLE, APS, and ITP. It suggested that the presence of anti-CD40L autoantibodies was associated with thrombocytopenia but not thromboembolism.

  7. Krause I, Blank M, Fraser A, et al.: The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiol 2005, 210:749–754.

    Article  CAS  Google Scholar 

  8. Turiel M, Sarzi-Puttini P, Peretti R, et al.: Thrombotic risk factors in primary antiphospholipid syndrome. A 5-year prospective study. Stroke 2005, 36:1490–1494.

    Article  PubMed  Google Scholar 

  9. Trappe R, Loew A, Thuss-Patience P, et al.: Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab—monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann Hematol 2005, doi 10.1007/ s00277-005-0028-6.

  10. Alves JD, Inanc M, Diz-Kucukkaya R, et al.: Thrombotic risk in patients submitted to splenectomy for systemic lupus erythematosus and antiphospholipid antibody syndromerelated thrombocytopenia. Eur J Int Med 2004, 15:162–167.

    Article  Google Scholar 

  11. Bladt V, Steengaard-Pedersen K, Poulsen LH, et al.: Late puerperal thrombohemorrhagic complications in a patient with antiphospholipid syndrome. Eur J Haematol 2004, 73:437–440. Case report of a patient who developed bleeding and thrombosis 5 weeks after an uncomplicated delivery on aspirin and low molecular weight heparin. She was successfully managed with high dose steroids and azathioprine while low molecular weight heparin was maintained.

    Article  PubMed  CAS  Google Scholar 

  12. Bongarzoni V, Annino L, Rovenda A, et al.: Risk of thromboembolism in patients with idiopathic autoimmune hemolytic disease and antiphospholipid antibodies: results from a prospective, case-control study. Haematologica 2005, 90:711–713.

    PubMed  Google Scholar 

  13. Giannouli S, Vougarelis M, Ziakas PD, et al.: Anemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis 2005, doi 10.1136/ard.2005.041673.

  14. Asherson RA, Espinoza G, Cervera R, et al.: Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics in 23 patients. Ann Rheum Dis 2005, 64:943–946.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, University of Pennsylvania School of Medicine, 36th and Spruce Streets, 504 Maloney Building, 19104, Philadelphia, PA, USA

    Sharon L. Kolasinski MD

Authors
  1. Sharon L. Kolasinski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sharon L. Kolasinski MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kolasinski, S.L. Prevalence of secondary hematologic disorders in the antiphospholipid syndrome: Impact on coagulation risk. Curr Rheumatol Rep 8, 95–99 (2006). https://doi.org/10.1007/s11926-006-0048-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-006-0048-9

Keywords

Search

Navigation